“…Like basiliximab, daclizumab has been shown to decrease the incidence of acute cellular rejection when administered as an induction agent (Hershberger et al, 2005;Nashan et al, 1999). Given the favorable side effect profile, it is tolerated well in recipients, irrespective of co-morbid conditions.…”